Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Arnay Sciences LLC currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, indicating that the company's current prosecution is distributed across different technical specialties. This variety requires a strategy that can adapt to the standards of multiple examination groups. The presence of 2 distinct art units suggests that the pending matters involve diverse technical aspects within the Biotechnology & Pharmaceuticals field.
The busiest examiner for the portfolio is TRAN, CHRISTINA L, who is responsible for 1 busiest examiner pending action. This accounts for half of the 2 pending office actions currently facing the company. Because there are 2 distinct examiners involved, the company must navigate different individual examination styles. Practitioners should be prepared to manage the 2 pending office actions with distinct approaches tailored to each examiner and art unit. This distributed structure requires careful coordination to maintain consistency across the company's Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, CHRISTINA L | 1 | 51.6% | +49.8% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17478293 | ANTISENSE OLIGONUCLEOTIDES FOR ALLELE SPECIFICITY | SULLIVAN, STEPHANIE LAUREN | 73d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17478293 | ANTISENSE OLIGONUCLEOTIDES FOR ALLELE SPECIFICITY | SULLIVAN, STEPHANIE LAUREN | 73d overdue |
| 17697081 | COMPOUNDS AND METHODS USEFUL FOR MODULATING GENE SPLICING | TRAN, CHRISTINA L | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17697081 | COMPOUNDS AND METHODS USEFUL FOR MODULATING GENE SPLICING | TRAN, CHRISTINA L | 1637 | §103 | Non-Final OA | — | Pending | Mar 17, 2022 |
| 17478293 | ANTISENSE OLIGONUCLEOTIDES FOR ALLELE SPECIFICITY | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112 | Final Rejection | 73d overdue | Pending | Sep 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArnay Sciences LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Christina L Tran has the most, with 1 of Arnay Sciences LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
